Link Björn-Christian, Reichelt Uta, Schreiber Matthias, Kaifi Jussuf T, Wachowiak Robin, Bogoevski Dean, Bubenheim Michael, Cataldegirmen Guel, Gawad Karim A, Issa Rana, Koops Susann, Izbicki Jakob R, Yekebas Emre F
Department of General, Visceral and Thoracic Surgery, University Medical Center of Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Ann Surg Oncol. 2007 Sep;14(9):2591-9. doi: 10.1245/s10434-007-9469-6. Epub 2007 Jun 5.
To assess the interaction between the expression of netrin-1 or of its receptors to the prognosis of ductal adenocarcinoma of the pancreas.
In 82 patients with resectable pancreatic adenocarcinoma who underwent curative operation, the expression patterns of netrin-1, deleted in colorectal carcinomas (DCC), UNC5H3, and neogenin were determined by immunohistochemical staining. Kaplan-Meier analysis was performed to assess the prognostic relevance of the examined expression patterns.
Median follow-up was 15 +/- 19.9 months (range, 4-108 months). Patients suffering from tumors with no or little expression of netrin-1 (n = 67) had a median recurrence-free survival of 10 months (95% CI, 7-13 months), while a middle to strong expression (n = 15) was associated with a significantly worse median recurrence-free survival of only four months (95% CI, three to five months, p = 0.0165). Overall and recurrence-free survival showed no significant differences between the different expression patterns of DCC, UNC5H3 or neogenin. Netrin-1 expression had significant impact (p = 0.001) on overall survival of patients suffering from poorly differentiated tumors. Stratification according to the nodal status revealed significant influence (p = 0.007) of UNC5H3 expression on the overall survival of patients with pN1 status.
Expression of netrin-1 has significant impact on time to tumor relapse in adenocarcinoma of the pancreas. Netrin-1 expression is associated with worse outcome in poorly differentiated pancreatic adenocarcinomas. Risk-stratification according to the UNC5H3 receptor expression pattern shows that node positive patients (pN1) with no to little UNC5H3 expression carry a significantly worse prognosis than those with middle to strong UNC5H3 expression.
评估netrin-1及其受体的表达与胰腺导管腺癌预后之间的相互作用。
对82例行根治性手术的可切除胰腺腺癌患者,采用免疫组织化学染色法检测netrin-1、结直肠癌缺失基因(DCC)、UNC5H3和新基因的表达模式。采用Kaplan-Meier分析评估所检测的表达模式与预后的相关性。
中位随访时间为15±19.9个月(范围4 - 108个月)。netrin-1无表达或低表达的肿瘤患者(n = 67)的中位无复发生存期为10个月(95%可信区间,7 - 13个月),而中度至强表达患者(n = 15)的中位无复发生存期明显更差,仅为4个月(95%可信区间,3 - 5个月,p = 0.0165)。DCC、UNC5H3或新基因的不同表达模式之间的总生存期和无复发生存期无显著差异。Netrin-1表达对低分化肿瘤患者的总生存期有显著影响(p = 0.001)。根据淋巴结状态分层显示,UNC5H3表达对pN1状态患者的总生存期有显著影响(p = 0.007)。
Netrin-1的表达对胰腺腺癌的肿瘤复发时间有显著影响。Netrin-1表达与低分化胰腺腺癌的不良预后相关。根据UNC5H3受体表达模式进行风险分层显示,UNC5H3无表达或低表达的淋巴结阳性患者(pN1)的预后明显比中度至强表达患者差。